SCHEMBL207809

SCHEMBL207809

CN(C)C1(Cc2ccc(Cl)cc2)CCC(NC(=O)CCC(=O)NCCc2c[nH]c3ccccc23)CC1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.53
HTT P42858 1/20 0.53
RECQL P46063 1/20 0.53
ALDH1A1 P00352 1/20 0.52
BCHE P06276 3/20 0.49
ACHE P22303 3/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
MTNR1A P48039 2/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
SIRT1 Q96EB6 1/20 0.49
KDM1A O60341 1/20 0.48
GOT1 P17174 1/20 0.48
GFER P55789 1/20 0.48
TRPV1 Q8NER1 1/20 0.47
HSD17B2 P37059 1/20 0.47
MAPT P10636 1/20 0.47
MAPK1 P28482 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL206020 0.91 ACHE (0.53) HPGDHTTRECQLALDH1A1BCHE
SCHEMBL251054 0.89 HPGD (0.52) HPGDHTTRECQLALDH1A1BCHE
SCHEMBL207608 0.87 BCHE (0.56) HPGDHTTRECQLBCHEACHE
SCHEMBL206304 0.84 CNR1 (0.44) HTTALDH1A1KMT2ANPC1
SCHEMBL205896 0.81 HPGD (0.52) HPGDHTTRECQLALDH1A1BCHE
SCHEMBL208300 0.81 LMNA (0.50) ALDH1A1MEN1KMT2ANPC1RAB9A
SCHEMBL205605 0.80 ACHE (0.50) HPGDHTTRECQLALDH1A1BCHE
SCHEMBL206738 0.79 TSHR (0.46) HPGDHTTALDH1A1KMT2A
SCHEMBL207613 0.79 SIGMAR1 (0.44) MEN1KMT2AMAPT
SCHEMBL5484530 0.78 MC4R (0.47) HPGDHTTRECQLBCHEACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US claimed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP claimed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US claimed
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US disclosed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP disclosed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US disclosed
EP-1745010-A1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2007-01-24 EP disclosed
WO-2005110974-A1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2005-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds PKD1, DDC, DPYD HPGD 96/4885HTT 422/4885RECQL 892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.